GlycoMimetics, Inc. (NASDAQ: GLYC) today announced that the European Commission, based on a favorable recommendation from the European Medicines Agency ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE